(TGTX) TG Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TGTX) TG Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This TG Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics to show how it competes in oncology and immunology markets; this page contains a real preview/sample of the analysis so you can assess style and content before buying—purchase the full version to get the complete ready-to-use report.
Product
BRIUMVI 2022 U.S. approval
BRIUMVI, TG Therapeutics' ublituximab-xiiy, won U.S. approval in 2022 for adults with relapsing forms of multiple sclerosis. It is the company’s only marketed product and the core of its commercial revenue base. In 2025, that single-asset profile kept TG Therapeutics highly dependent on BRIUMVI for sales growth and cash flow.
Relapsing forms of multiple sclerosis
BRIUMVI is TG Therapeutics, Inc.'s lead neurology brand for relapsing forms of multiple sclerosis (RMS), including relapsing-remitting disease, and that keeps physician care focused on long-term repeat infusion management. In ULTIMATE I/II, it cut annualized relapse rates by 59% and 49% versus teriflunomide. RMS is the main commercial lane for TG Therapeutics, Inc.
Glycoengineered monoclonal antibody
Ublituximab is TG Therapeutics, Inc.'s glycoengineered monoclonal antibody, built to improve target binding and boost anti-CD20 activity versus older MS and B-cell depletion drugs. In TG Therapeutics, Inc.'s 2025 results, BRIUMVI stayed the growth engine, with annual sales still scaling from a 2022 FDA launch. That gives the product a clear premium, differentiated place in the MS market.
TG-1701 BTK inhibitor
TG-1701 is an oral, covalently bound BTK inhibitor that TG Therapeutics says screens as more selective than ibrutinib in lab testing. It broadens the pipeline beyond BRIUMVI, TG Therapeutics’ only marketed product, so it matters for future autoimmune and hematology revenue. In the 4P mix, the product story is about a differentiated next-step oral therapy, not current sales.
- Oral, covalent BTK inhibitor
- More selective than ibrutinib in screening
- Pipeline expansion beyond BRIUMVI
- No approved revenue yet
TG-1801 CD47 CD19 bispecific
TG-1801 is TG Therapeutics, Inc.’s CD47/CD19 bispecific antibody, built to attack B-cell malignancy biology and help tumors evade immune clearance. In the Product part of the mix, it adds a differentiated, science-led asset to a pipeline that also includes licensed preclinical BET, IRAK4, and GITR programs.
Targets CD47 and CD19 in one molecule.
Aims at B-cell cancers and immune evasion.
Supports a broader preclinical R&D pipeline.
BRIUMVI Fuels TG Therapeutics’ 2025 Revenue Surge
BRIUMVI is TG Therapeutics, Inc.'s only marketed product and the Product core of the mix. In 2025, it drove nearly all revenue, with net product sales of $495.2 million, up 93% year over year. Its key use is relapsing forms of multiple sclerosis, a repeat-treatment market with long care cycles.
| Product | 2025 Sales | Status |
|---|---|---|
| BRIUMVI | $495.2M | Approved |
What is included in the product
Detailed Word Document
A concise, company-specific breakdown of TG Therapeutics, Inc.'s Product, Price, Place, and Promotion strategies, grounded in real-world market positioning.
Editable Excel File
Condenses TG Therapeutics’ 4Ps into a quick, easy-to-grasp view for faster strategic alignment and decision-making.
Reference Sources
Cites primary pharma reports, FDA filings, clinical trial data, and market benchmarks to let investors verify TG Therapeutics’ assumptions quickly and confidently.
Place
U.S. neurology specialty channel
BRIUMVI is sold through U.S. neurologists and MS centers, so TG Therapeutics, Inc. depends on prescription access, prior auth, and specialty infusion sites rather than retail shelves. Multiple sclerosis affects about 1 million people in the U.S., and the channel is concentrated in specialists who decide therapy. That makes field support, reimbursement help, and center access the core of place strategy.
Infusion centers
BRIUMVI is given by intravenous infusion in healthcare settings, so infusion centers are a key place in TG Therapeutics, Inc. marketing mix. This channel fits a non-retail drug: it supports controlled delivery, close monitoring, and better adherence. TG Therapeutics, Inc. also benefits because infusion-site access can shape starts and repeat dosing for a therapy aimed at relapsing forms of multiple sclerosis.
Hospital outpatient departments
Hospital outpatient departments are a key access point for TG Therapeutics, Inc.’s anti-CD20 therapy, because they handle the first loading infusions and the twice-yearly maintenance doses. These sites also fit payer rules and specialty-biologic workflows, which matters when treatment is given in a reimbursed hospital setting. In 2025, TG Therapeutics, Inc. kept expanding BRIUMVI use across infusion channels as demand for lower-frequency dosing stayed strong.
Specialty pharmacy and buy-and-bill access
TG Therapeutics, Inc. uses specialty distribution and buy-and-bill access for BRIUMVI, its infused anti-CD20 biologic for relapsing MS. This model routes product through specialty channels, so providers can manage prior auth, shipment, and claims in one flow. It fits a high-touch therapy where reimbursement and infusion-site support drive uptake.
Specialty distribution supports access control.
Buy-and-bill fits infusion reimbursement.
Prior auth and claims are coordinated.
Partnered ex-U.S. markets
TG Therapeutics, Inc. uses partnered ex-U.S. markets to extend BRIUMVI without building a heavy direct sales network. Licensing and collaboration deals let local partners handle development and commercialization in selected regions, which cuts retail distribution costs and speeds market access.
In 2025, this model kept TG Therapeutics, Inc. focused on the U.S., while partners carried the burden of country-specific launch work, pricing, and reimbursement. That matters because ex-U.S. rollout in MS is slow and costly, so shared geography reduces fixed operating risk.
- Lower capex, lower launch cost
- Local partner handles access
- Faster regional commercialization
- Less need for retail footprint
BRIUMVI’s Access Runs Through Specialists and Infusion Centers
TG Therapeutics, Inc. places BRIUMVI in specialist neurology offices, infusion centers, and hospital outpatient departments, not retail pharmacies. That fits its IV, buy-and-bill model and helps manage prior auth, shipping, and claims. With about 1 million U.S. people living with MS, access is concentrated in a small set of prescribers and sites.
| Place | 2025 impact |
|---|---|
| Specialists | Drive starts |
| Infusion sites | Enable dosing |
| Hospital OPDs | Support reimbursement |
What You See Is What You Get
TG Therapeutics, Inc. Reference Sources
The preview shown here is the actual TG Therapeutics, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the complete, editable document ready for immediate use.
Promotion
Physician detailing
TG Therapeutics, Inc. uses physician detailing to educate neurologists and MS specialists on BRIUMVI’s efficacy, safety, and dosing. The pitch highlights its 2 starter infusions, then 1 infusion every 24 weeks, which fits a specialty biologic. This direct channel matters: BRIUMVI generated $494.5 million in net product revenue in 2024.
Medical congress data
TG Therapeutics uses medical congress data to turn BRIUMVI evidence into prescriber trust. In ULTIMATE I/II, 1,094 relapsing MS patients showed a 59% and 49% lower annualized relapse rate versus teriflunomide, so major neurology meetings like ECTRIMS and AAN are the best stage for head-to-head updates. That helps support payer review and clinician adoption.
Patient awareness in multiple sclerosis
TG Therapeutics, Inc. promotes BRIUMVI through RMS disease-awareness messaging that stresses relapse control and lower treatment burden. This matters because RMS makes up about 85% of multiple sclerosis cases, and the U.S. has nearly 1 million people living with MS. Branded patient education on infusion convenience can lift demand before the physician visit.
Access and reimbursement support
BRIUMVI is a specialty infused MS therapy, so TG Therapeutics, Inc. promotes it with hub services, benefit verification, prior-authorization help, and copay support to cut start-up friction after the first script. These access tools matter because BRIUMVI is given as 1 infusion every 6 months after the initial doses, so each delay can slow uptake. The goal is simple: fewer insurance hurdles, faster treatment starts.
- Hub services support onboarding
- Benefit checks speed coverage
- Copay help lowers out-of-pocket cost
Investor relations and press releases
TG Therapeutics uses earnings calls, SEC filings, and BRIUMVI updates to show sales traction and pipeline progress, and that can move valuation fast for a small biopharma. Its 2024 BRIUMVI net product sales reached $344.0 million, so every quarterly update matters to investors. This promotion channel is especially important because commercialization speed and trial milestones can change the equity story quickly.
- Quarterly earnings calls set the tone.
- SEC filings add hard, audited data.
- Product updates track sales and milestones.
BRIUMVI’s Simple Pitch: Strong MS Control, Fewer Infusions
TG Therapeutics, Inc. promotes BRIUMVI through physician detailing, congress data, patient education, and access support to speed adoption in relapsing MS. The message is simple: strong relapse control, 2 starter infusions, then 1 infusion every 24 weeks.
| Channel | Role | Key data |
|---|---|---|
| Detailing | Educate prescribers | 2024 sales: $494.5M |
| Congresses | Build trust | 1,094 patients in ULTIMATE I/II |
| Access support | Reduce friction | Copay and PA help |
Price
150 mg day 1 and 450 mg day 15
BRIUMVI starts with two loading infusions: 150 mg on day 1 and 450 mg on day 15, for 600 mg in the first month. That front-loads the start-up dose, so early-cycle spend and infusion scheduling are concentrated upfront. After that, the maintenance dose is 450 mg every 24 weeks, which helps spread cost later in the treatment cycle.
450 mg every 24 weeks
450 mg every 24 weeks supports TG Therapeutics, Inc.'s maintenance plan with twice-yearly dosing, so patients and sites of care face fewer infusion visits. In 2025, this lower-touch schedule can reduce chair time and staffing load while keeping treatment continuity. It also helps payer talks by framing value around durable control and lower administration burden.
1-hour maintenance infusion
TG Therapeutics, Inc.'s 1-hour maintenance infusion for BRIUMVI cuts chair time versus many specialty infusions, which can lower indirect costs for infusion centers and patients. In a drug priced at $245 per 100 mg vial at WAC, saving an hour per visit can matter in pricing talks because time is real capacity.
Specialty-biologic reimbursement
BRIUMVI is priced and reimbursed like an infused specialty biologic, so the real net price depends on payer access, not just the list price. Coverage usually runs through the medical benefit with prior authorization, and that makes infusion-center contracting and claims approval central to TG Therapeutics, Inc.'s realized revenue.
- Medical benefit, not retail pharmacy
- Prior authorization often required
- Payer access drives net price
- Infusion reimbursement shapes adoption
Copay and patient support
TG Therapeutics, Inc. uses copay and patient support to soften out-of-pocket shock for BRIUMVI patients. These programs can trim deductible and coinsurance exposure, which matters in U.S. employer plans where the average single deductible was $1,787 in 2024.
- Helps with deductible pain
- Reduces coinsurance exposure
- Fits high-cost biologics
List price is not net price, and support can make a branded biologic more accessible without cutting the sticker price.
BRIUMVI Pricing Starts Around $1,470 in Month One
BRIUMVI’s price sits in specialty biologic territory: WAC is $245 per 100 mg vial, so a 600 mg first month starts near $1,470 before rebates, then 450 mg every 24 weeks eases later-cycle spend.
| Metric | Value |
|---|---|
| WAC per 100 mg | $245 |
| First-month dose | 600 mg |
| Maintenance dose | 450 mg q24w |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.